Table 2. Summary of diagnostic metrics to detect EGFR mutation, exon-19 deletion, and exon-21 L858R mutation in the training and test cohort.
| Mutation | Clinical information | Information criterion | Training (n=210) | Testing (n=53) | |||||
|---|---|---|---|---|---|---|---|---|---|
| AUC | Cut-off value | AUC | Sensitivity | Specificity | Accuracy | ||||
| EGFR | No | Akaike | 0.73 (0.66–0.79) | 0.71 | 0.70 (0.56–0.82) | 82.8% (64.2–94.2%) | 41.7% (22.1–63.4%) | 64.2% (49.8–76.9%) | |
| Bayesian | 0.71 (0.65–0.77) | 0.67 | 0.65 (0.51–0.78) | 84.0% (63.9–95.5%) | 39.3% (21.5–59.4%) | 60.4% (46.0–73.6%) | |||
| Yes | Akaike | 0.78 (0.72–0.83) | 0.68 | 0.76 (0.63–0.87) | 90.3% (74.3–98.0%) | 54.6% (32.2–75.6%) | 75.5% (61.7–86.2%) | ||
| Bayesian | 0.77 (0.70–0.82) | 0.63 | 0.76 (0.62–0.84) | 92.9% (76.5–99.1%) | 52.0% (31.3–72.2%) | 73.6% (59.7–84.7%) | |||
| Exon-19 del | No | Akaike | 0.75 (0.69–0.81) | 0.40 | 0.70 (0.56–0.82) | 50.0% (24.7–75.4%) | 83.8% (68.0–93.8%) | 73.6% (59.7–84.7%) | |
| Bayesian | 0.66 (0.59–0.73) | 0.24 | 0.65 (0.50–0.77) | 38.1% (18.1–61.6%) | 81.3% (63.6–92.8%) | 64.2% (49.8–76.9%) | |||
| Yes | Akaike | 0.74 (0.68–0.80) | 0.30 | 0.69 (0.55–0.81) | 43.5% (23.2–65.5%) | 86.7% (69.3–96.2%) | 67.9% (53.7–80.1%) | ||
| Bayesian | 0.65 (0.58–0.71) | 0.27 | 0.64 (0.49–0.77) | 36.0% (18.0– 57.5%) | 82.1% (63.1–93.9%) | 60.4% (46.0–73.6%) | |||
| Exon-21 L858R | No | Akaike | 0.78 (0.71–0.83) | 0.26 | 0.65 (0.50–0.77) | 48.2% (28.7–68.1%) | 65.4% (44.3–82.8%) | 56.6% (42.3–70.2%) | |
| Bayesian | 0.75 (0.69–0.81) | 0.41 | 0.65 (0.50–0.77) | 52.0% (31.3–72.2%) | 67.9% (47.7–84.1%) | 60.4% (46.0–73.6%) | |||
| Yes | Akaike | 0.77 (0.70–0.82) | 0.29 | 0.66 (0.52–0.79) | 53.9% (33.4–73.4%) | 70.4% (49.8–86.3%) | 62.3% (47.9–75.2%) | ||
| Bayesian | 0.75 (0.69–0.81) | 0.30 | 0.65 (0.50–0.77) | 52.0% (31.3–72.2%) | 67.9% (47.7–84.1%) | 60.4% (46.0–73.6%) | |||